Psychedelic-Assisted Therapies

FDA and Reagan-Udall Foundation are hosting a virtual public meeting on psychedelic research titled Advancing Psychedelic Clinical Study Design, which aims to explore empirical approaches to address issues in drug development. The U.S. Food and Drug Administration (FDA) together with the Reagan-...

Numerous companies in the psychedelics industry are essentially advancing research on compounds that have a history of past use. Some of them are particularly focusing on the believed effects that millenary plants hold and targeting contemporary mental health conditions by performing a scientific...

New Study Reveals Suggestibility’s Role In Antidepressant Effects Of Psilocybin Therapy A new study led by Balázs Szigeti and with involvement of researchers Brandon Weiss, Fernando E Rosas, David Erritzoe, David Nutt and Robin Carhart-Harris found evidence of suggestibility predicting an...

Welcome to Benzinga’s psychedelics headlines roundup. This is our pick of must-read news items from weeks three and four of January 2024. See previous edition Psychedelics Headlines: MDMA & Coping Skills In PTSD, LSD’s Perceived Risks, Knowledge Gaps, Surveys & More  Research...

Welcome to the inaugural episode of the Benzinga Psychedelics Podcast. In this exciting kickoff, we're joined by Joel Latham, experienced biotech industry leader and CEO of Incannex Healthcare (NASDAQ:IXHL). Dive into our engaging conversation as we explore Incannex's strategic expansion into...

A new study led by Balázs Szigeti and with involvement of researchers Brandon Weiss, Fernando E Rosas, David Erritzoe, David Nutt and Robin Carhart-Harris found evidence of suggestibility predicting an antidepressant response for patients receiving psilocybin therapy. The study aimed to understand...

The new treatments, given to two people under the guidance of Dr. Eli Kotler and Dr. Ted Cassidy, are framed within Australia's Therapeutic Goods Administration (TGA) program authorizing psychiatrists to provide these medicines for specific mental health conditions. Kotler and Cassidy, early...

Psychedelics biotech Cybin Inc. (NYSE:CYBN) has received clearance from the Food and Drug Administration (FDA) on its Investigational New Drug (IND) application for CYB004, its novel deuterated DMT molecule for Generalized Anxiety Disorder (GAD) treatment. This will enable the company to initiate a...

State-level psychedelics policy reform is moving fast throughout the U.S. Here’s a recap from our previous update and as of Jan. 18, 2024: California: After unanimously clearing the Assembly’s Health Committee on Jan. 9, AB 941 was re-referred to the Appropriations Committee, which on...

Psychedelics mental healthcare company Numinus Wellness (OTCQX: NUMIF) posted its financial results for the three months ended Nov. 30, 2023. Q1 numbers show: Cash position of $3.5 (CA$4.7) million by Nov. 30, 2023, vs. $6.35 million held by August 31 (immediately prior fiscal quarter...

Welcome to Benzinga's weekly psychedelics headlines roundup. This is our pick of must-read news items from the second week of January 2024.  See previous edition: Psychedelics Headlines: Magic Mushrooms For Sexual Wellbeing, The DEA's Stance, The Therapist's Role & More...

Earlier this week, biopharma company Mind Medicine (MindMed) (NASDAQ: MNMD) released latest clinical trial results on repeated sub-perceptual doses of its LSD compound, MM-120, in adults with ADHD. The company also provided a corporate update and outlook for 2024. Clinical Development: Present...

The emerging psychedelics industry is expanding rapidly across the globe. With research demonstrating promising therapeutic potential for substances like psilocybin and MDMA to treat mental health conditions, this sector has attracted growing attention and investment.  Recent research data...

Clinical-stage biopharma company Cybin Inc. (NYSE: CYBN) announced positive safety and efficacy data from its Phase 1 studies of CYB004 (intravenous administration) and SPL028 (intravenous and intramuscular administration) in healthy volunteers.  Both compounds are novel deuterated DMT...

Welcome to Benzinga's weekly psychedelics news roundup. We have pulled together several must-read news items from the last week of December 2023 and the first of January 2024.  Research Disorders due to substance use: Hallucinogens and MDMA-related...